UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/715,100	11/17/2003	Dharma R. Kodali	07148-072003	5876	
26191 FIGU & DICH	26191 7590 04/17/2007 FISH & RICHARDSON P.C.			EXAMINER	
PO BOX 1022			BAGGOT, BRENDAN O		
MINNEAPOLIS, MN 55440-1022			ART UNIT	PAPER NUMBER	
			1638		
SHORTENED STATUTO	RY PERIOD OF RESPONSE	MAIL DATE	. DELIVER	Y MODE	
31 1	DAYS	04/17/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

· · · · · · · · · · · · · · · · · · ·	Application No.	Applicant(s)			
	10/715,100	KODALI ET AL.			
Office Action Summary	Examiner	Art-Unit			
	Brendan O. Baggot	1638			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	I. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status	•				
Responsive to communication(s) filed on <u>17 Not</u> This action is FINAL . 2b) ☑ This Since this application is in condition for allowant closed in accordance with the practice under E	action is non-final. ace except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 24-44 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 24-44 are subject to restriction and/or Application Papers 9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access	vn from consideration. election requirement.	Examiner.			
Applicant may not request that any objection to the orection Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Expression 11).	drawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa				

٤

Art Unit: 1638

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claim 41, drawn to drawn to a method of crossing oleic acid desaturase mutant plants with altered monounsaturated fatty acids, classified in class 800, subclass 264, for example.
- II. Claim 42, drawn to drawn to a method of crossing linoleic acid desaturase mutant plants with altered monounsaturated fatty acids, classified in class 800, subclass 276, for example.
- III. Claim 43, drawn to a method of crossing a plant comprising a transgene encoding oleic acid desaturase, classified in class 800, subclass 281, for example.
- IV. Claim 44, drawn to a method of crossing a plant with linoleic acid desaturase, classified in class 800, subclass 278, for example.
- 1. Claims 24-40 link(s) inventions I-IV. The restriction requirement between the linked inventions is **subject to** the nonallowance of the linking claim(s), claims 24-40. Upon the indication of allowability of the linking claim(s), the restriction requirement as to the linked inventions **shall** be withdrawn and any claim(s) depending from or otherwise requiring all the limitations of the allowable linking claim(s) will be rejoined and fully examined for patentability in accordance with 37 CFR 1.104 Claims that require all the limitations of an allowable linking claim will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is

Page 3

Art Unit: 1638

earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, the allowable linking claim, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I-IV are directed to related processes. The related inventions are distinct if the (1) the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect; (2) the inventions do not overlap in scope, i.e., are mutually exclusive; and (3) the inventions as claimed are not obvious variants. See MPEP § 806.05(j). In the instant case, the inventions as claimed use different starting materials not used by any other Group. I and II use mutant plants whereas III and IV use isolated nucleotides and transformation methods. I and II use different polynucleotide starting materials from each other: namely oleic acid desaturase versus linoleic acid desaturase. III and IV are likewise distinct from each other because they use different polynucleotide starting materials: namely oleic acid desaturase mutant versus linoleic acid desaturase mutant.

Application/Control Number: 10/715,100 Page 4

Art Unit: 1638

Furthermore, the inventions as claimed do not encompass overlapping subject matter and there is nothing of record to show them to be obvious variants.

- 3. Because these inventions are classified in different classes and subclasses, are distinct for the reasons given above, have acquired a separate status in the art because of their recognized divergent subject matter and/or fields of search, the search for one is not required by the others, and because a search of all the Groups would place an undue search burden on the Office, restriction for examination purposes as indicated is proper.
- 4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 5. The election of an invention or species may be made with or without traverse. To reserve the right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.
- 6. Should Applicant traverse on the ground that the inventions or species are not patentably distinct, Applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instant, if the examiner finds on of the inventions unpatentable over the prior art, the evidence or admissions may be used in a rejection under 35 U.S.C. §103(a) of the other invention.

Application/Control Number: 10/715,100

Art Unit: 1638

7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Page 5

8. Applicants are reminded that nucleotide sequences encoding different proteins or comprising different regulatory sequences are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brendan O. Baggot whose telephone number is 571/272-5265. The examiner can normally be reached on Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on 571/272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Brendan O. Baggøt

Patent Examiner

Art Unit 1638

David T. Fox

Primary Examiner

Art Unit 1638

bob